A Null CBD Cortical-Excitability Test Does Not Resolve Clinical Seizure Efficacy

forensic toxicology working group members October 28, 2026 Forensic Toxicology

CBD did not significantly alter the main TMS–EMG measures in a healthy-volunteer experiment. That null result does not, by itself, establish that CBD has no intrinsic antiseizure effect in patients or that every benefit must come from another drug interaction.

The trial’s actual endpoints

Twenty-five healthy men received single oral doses of 30 mg CBD, 700 mg CBD and placebo in a randomized, double-blind crossover design. Transcranial magnetic stimulation was combined with muscle and brain electrical recordings, alongside a CNS test battery and pharmacokinetic sampling.

These procedures measured responses to stimulation and selected functional tasks. The trial did not measure seizure frequency in people with epilepsy.

A largely null pattern included electrical signals

Single- and paired-pulse TMS–EMG parameters did not show significant CBD effects. The CNS battery also did not demonstrate significant sedative effects under the tested conditions.

Some TMS–EEG clusters differed at particular doses and times. The authors considered their physiological interpretation uncertain and discussed possible chance or artifact for a low-dose finding. Saying ‘no brain effect of any kind’ would therefore be too broad.

Surrogate and clinical conclusions differ

A surrogate measure is useful when its relationship to the clinical question is established. Absence of the expected stimulation signature may narrow a mechanism hypothesis without excluding all mechanisms or all treatment-responsive disease states.

The experiment also did not directly randomize a CBD–clobazam interaction. Attributing all clinical efficacy to clobazam would exceed what this design independently tested.

The appropriate conclusion is specific to healthy men, single doses and these assays. Neither a null sedation battery nor a null excitability measure establishes unrestricted safety-sensitive performance in patients taking multiple medicines.